Medtronic (NYSE:MDT) said today that it won 510(k) clearance from the FDA for its Accurian radiofrequency nerve ablation device for treating chronic pain.
“Medtronic has a long-established track record of bringing to market improved options to support clinicians with state-of-the-art technology, like the Accurian RF ablation system, which was designed for consistency and efficiency,” pain therapies president Dr. Marshall Stanton said in prepared remarks. “Medtronic is committed to advancing the treatment of pain as we introduce new options to help patients throughout the care continuum.”
“The Accurian RF ablation platform is a significant addition in my practice because I know I’ll get the same lesion every time in every channel due to how responsive the generator is in managing power and temperature,” added Dr. Leo Kapural of Winston-Salem’s Carolinas Pain Institute & Center for Clinical Research. “RF ablation requires both precision and flexibility. Accurian is intuitive and easy to use and enables me to easily upgrade the system and perform enhanced lesions with cooled RF probes.”
